Clinical Trial Update: Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction [Phase 2]

View source ↗

Summary

The update covers the Phase 2 study of CDR132L for patients with reduced left ventricular ejection fraction after acute myocardial infarction, focusing on effic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction
• Myocardial Infarction

Drugs mentioned

• CDR132L

Snippet

Sponsor: Cardior Pharmaceuticals GmbH | Conditions: Myocardial Infarction, Acute, Heart Failure, Left Sided | Phase 2 | Status: COMPLETED